27 August 2023 - Myeloma New Zealand is welcoming Pharmac's announcement of more blood cancer medicines, but says the country is still well behind the rest of the world.

Lenalidomide is already available to some myeloma patients who meet certain treatment criteria, but Myeloma New Zealand chair Barbara Horne said the potential for expanded access to this medicine was welcomed.

Pomalidomide however is not currently funded.

Read Radio New Zealand article